Transdermal Platform PassPort Technologies offers a unique transdermal delivery platform (PassPort System) that enables needle-free administration and potential drug repositioning opportunities, presenting a compelling value proposition for pharma companies seeking alternative routes of administration for approved therapeutics.

Collaboration Potential The company has a history of research partnerships, including a collaboration with Arcturus Therapeutics, highlighting openness to co-development opportunities that could accelerate adoption with biopharma partners and reduce time-to-market risks.

Niche Specialty With a focus on delivering biologics and large molecules (peptides, oligonucleotides, proteins) via a micoporation-based transdermal system, PassPort targets areas often limited to injections, suggesting opportunities with specialty biologics players looking to improve patient experience.

Early-Stage Funding Current revenue is under one million, indicating a startup/early-stage profile with potential for strategic partnerships, licensing deals, or collaboration-driven funding to scale platform applications and drive pilot programs.

Targeted Industries Given its pharmaceutical manufacturing focus and global tech stack readiness (cloud, security, PWA), the company could pursue partnerships with mid-to-large pharma firms seeking to modernize administration routes for existing products or accelerate development of new modalities.